Compliance to lipid-lowering therapy in patients with high and extremely high cardiovascular risk
https://doi.org/10.24884/1609-2201-2025-104-1-92-95
About the Authors
K. V. Legostaeva
Pavlov University
Russian Federation
Russian Federation
Kristina V. Legostaeva
6–8, L’va Tolstogo str., Saint Petersburg, 197022
A. N. Kulikov
Pavlov University
Russian Federation
Russian Federation
Alexandr N. Kulikov, Dr. of Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal diseases with the Clinic named after Academician M. D. Tushinsky
6–8, L’va Tolstogo str., Saint Petersburg, 197022
References
1. Sheng C. S., Miao Y., Ding L. et al. Prognostic significance of visitto-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus. Lipids Health Dis. 2022;21(1):19. https://doi.org/10.1186/s12944-022-01628-8.
2. Morisky D. E., Green L. W., Levine D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. https://doi.org/10.1097/00005650-198601000-00007.
Review
For citations:
Legostaeva K.V., Kulikov A.N. Compliance to lipid-lowering therapy in patients with high and extremely high cardiovascular risk. New St. Petersburg Medical Records. 2025;(1):92-95. (In Russ.) https://doi.org/10.24884/1609-2201-2025-104-1-92-95
Views:
15
Email this article 